Moxetumomab pasudotox - CAS 1020748-57-5 Catalog number: BADC-01612

Moxetumomab pasudotox is a pioneering therapeutic agent in the treatment of certain hematological cancers, particularly acute lymphoblastic leukemia (ALL) and hairy cell leukemia (HCL). This recombinant immunotoxin uniquely combines the specific targeting capabilities of an antibody fragment with the potent cytotoxic effects of a bacterial toxin. By fusing the Fv fragment of an anti-CD22 monoclonal antibody to a truncated form of Pseudomonas exotoxin A (PE38), Moxetumomab pasudotox specifically targets CD22, a cell surface antigen abundantly expressed on B-lymphocytes, including malignant B-cells in leukemia. This targeted approach enhances the selectivity and reduces systemic toxicity, distinguishing Moxetumomab pasudotox as a powerful tool in targeted cancer therapy.

The primary application of Moxetumomab pasudotox lies in the treatment of acute lymphoblastic leukemia (ALL), particularly in patients who have relapsed or are refractory to conventional treatments. ALL is characterized by the overproduction of immature lymphocytes, and CD22 is a suitable target due to its high expression on these malignant cells. Upon binding to CD22, Moxetumomab pasudotox is internalized into the leukemia cells. Once inside, the PE38 fragment inhibits protein synthesis by catalyzing the ADP-ribosylation of elongation factor 2, leading to cell death. This mechanism of action allows for a direct assault on cancer cells, paving the way for potential remissions in patients with limited treatment options.

In addition to ALL, Moxetumomab pasudotox has shown considerable efficacy in treating hairy cell leukemia (HCL), a rare type of B-cell leukemia. In clinical trials, the immunotoxin demonstrated significant response rates, including complete remissions in a notable proportion of patients who had exhausted other therapies. This success underscores the drug's utility in targeting malignancies with distinct antigen profiles, offering a lifeline to patients with difficult-to-treat cancers. The specificity of Moxetumomab pasudotox for CD22 also helps maintain a favorable safety profile compared to traditional chemotherapies, reducing off-target effects and improving the quality of life for patients undergoing treatment.

As research continues, Moxetumomab pasudotox holds the promise of expanding its therapeutic applications beyond ALL and HCL. Investigations into combining this immunotoxin with other therapeutic agents, including chemotherapeutics and immunomodulatory drugs, are underway to enhance its efficacy and overcome resistance mechanisms. Additionally, ongoing studies aim to explore its potential in other CD22-positive hematological malignancies, thereby broadening its impact. Moxetumomab pasudotox exemplifies the innovative approach of combining targeted therapy with the cytotoxic power of immunotoxins, demonstrating a significant advancement in personalized cancer treatment strategies and offering hope to patients with challenging forms of leukemia.